Results 61 to 70 of about 187,458 (237)

The Different Faces of Chronic Lymphocytic Leukemia -Two Clinical Cases [PDF]

Journal of Biomedical & Clinical Research, 2020
Chronic lymphocytic leukemia is one of the most common types of leukemia affecting adults over 65 years of age [1]. The disease is a part of the so-called indolent lymphomas and has a variable clinical course, defined by many factors.
Vanya Popova, Kalina Ignatova, Dobromir Nguen, Pencho Tonchev, Doroteya Todorieva, Lachezar Bogdanov   +5 more
doaj   +3 more sources

MOESM11 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

, 2019
Additional file 11: Methods S1. Procedures of mouse experiments.
Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Carian Boorsma, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam   +13 more
openaire   +1 more source

Characterization of the effects of BTK inhibition and monocyte-produced IL-8 on the hematopoietic stem cell niche [PDF]

, 2020
Hematopoietic stem and progenitor cells (HSPCs) are multipotent stem cells that give rise to all blood cell lineages. During early zebrafish development, HSPCs interact closely with endothelial cells in an endothelial niche known as the Caudal ...
Belardo, Alexander
core  

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells [PDF]

, 2015
Background: Roughly 80% of patients with acute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the oral BTK inhibitor ibrutinib in vitro.
Advani, Bendall, Burger, Burnett, Byrd, Chung, Dasmahapatra, de Rooij, de Weers, Dohner, Dos Santos, Dubovsky, Döhner, Fiedler, Fiedler, Gao, Gu, Hahn, Honda, Horwood, Ikeda, Ito, Juliusson, Kim, Koketsu, Kvinlaug, Ma, Matsunaga, Meng, Miettinen, Oellerich, Rushworth, Rushworth, Rushworth, Rushworth, Rushworth, Schmidt, Sivina, Sun, Tai, Tomasson, Wang, Wang, Welch   +43 more
core   +1 more source

Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease

Acta Neuropathologica, 2020
Anti-CD20-mediated B-cell depletion effectively reduces acute multiple sclerosis (MS) flares. Recent data shows that antibody-mediated extinction of B cells as a lasting immune suppression, harbors the risk of developing humoral deficiencies over time ...
Sebastian Torke, Roxanne Pretzsch, Darius Häusler, P. Haselmayer, R. Grenningloh, U. Boschert, W. Brück, Martin S. Weber   +7 more
semanticscholar   +1 more source

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial

ACR Open Rheumatology, 2022
Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of evobrutinib in ...
D. Wallace, T. Dörner, D. Pisetsky, J. Sánchez-Guerrero, Anand C Patel, Dana Parsons-Rich, Claire Le Bolay, E. Drouin, A. Kao, H. Guehring, M. Dall'Era   +10 more
semanticscholar   +1 more source

Platelet Rubicon Bidirectional Regulation of GPVI and Integrin αIIbβ3 Signaling Mitigates Stroke Infarction Without Compromising Hemostasis

Advanced Science, EarlyView.
This study identifies Rubicon as a key platelet protein that bidirectionally regulates GPVI and integrin αIIbβ3 signaling. Platelet Rubicon protects against cerebral ischemia‐reperfusion injury by limiting infarction without increasing hemorrhage.
Xiaoyan Chen, Jingke Li, Yangyang Liu, Li Li, Xin Deng, Yilin Sheng, Xianyu Zhu, Xiao Jiang, Wei Li, Xueli Cai, Qiming Sun, Hu Hu   +11 more
wiley   +1 more source

MOESM8 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

, 2019
Additional file 8: Figure S8. Increased proportions of IgA+ GC B-cells and IgA+ plasma cells in lungs in mice exposed to saline and bleomycin. (A) Flow cytometric quantification of IgA+ GC B-cells (CD19+CD95+IgDlowIgA+) as percentage of GC B-cells and (B) IgA+ plasma cells (CD19lowCD138+IgA+) as percentage of plasma cells in lungs of mice exposed to ...
Heukels, Peter, Hulst, Jennifer, Nimwegen, Menno, Carian Boorsma, Melgert, Barbro, Thusen, Jan, Blink, Bernt, Hoek, Rogier, Miedema, Jelle, Neys, Stefan, Corneth, Odilia, Hendriks, Rudi, Wijsenbeek, Marlies, Kool, Mirjam   +13 more
openaire   +1 more source

Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

Nature Communications, 2015
Inflammasome activation has been implicated in various inflammatory diseases including post-ischaemic inflammation after stroke. Inflammasomes mediate activation of caspase-1, which subsequently induces secretion of pro-inflammatory cytokines such as IL ...
Minako Ito, T. Shichita, Masahiro Okada, Ritsuko Komine, Yoshiko Noguchi, Akihiko Yoshimura, R. Morita   +6 more
semanticscholar   +1 more source

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

Respiratory Medicine Case Reports, 2017
We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia.
Benjamin Arthurs, MD, Kathy Wunderle, MD, Maylee Hsu, MD, Suil Kim, MD, PhD   +3 more
doaj   +1 more source